🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Johnson & Johnson Enterprise Innovation clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK, China and India registers with Johnson & Johnson Enterprise Innovation as lead sponsor. Synced 26 Sep 2026
6Current trials
5Recruiting now
8Drugs in these trials
4Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Johnson & Johnson Enterprise Innovation is the lead sponsor of 6 current clinical trials in our USA, UK, China and India registers. 5 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Cetrelimab, JNJ-90301900 and Carboplatin. The most-studied condition is Neoplasms.

Company profiles on this site (news, sites, medicines, approvals): Johnson & Johnson Ireland (IE) →Johnson & Johnson (US) →

ClinicalTrials.gov trials by status

  • Recruiting583%
  • Active, closed117%

Trials by phase

  • Phase 1467%
  • Phase 2117%
  • Phase 3117%
01

Clinical trials sponsored by Johnson & Johnson Enterprise Innovation

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908 · Carcinoma, Non-Small-Cell Lung
Phase 2 Recruiting 2024-12 UK, USA, China
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173 · ClinicalTrials.gov ↗ · Carcinoma, Squamous Cell
Phase 3 Recruiting 2021-12 UK, USA, India, China
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
NCT06311578 · Neoplasms
Phase 1 Recruiting 2024-04 USA
A Study of JNJ-1761981 in Participants With Solid Tumors
NCT07525141 · ClinicalTrials.gov ↗ · Neoplasms
Phase 1 Recruiting 2026-05 USA
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07219212 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck
Phase 1 Recruiting 2026-01 USA
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786 · ClinicalTrials.gov ↗ · Carcinoma, Non-small-Cell Lung
Phase 1 Active, closed 2023-11 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Johnson & Johnson Enterprise Innovation trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Johnson & Johnson Enterprise Innovation trials

5 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA65
Clinical trials in UK22
Clinical trials in China22
Clinical trials in India11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Neoplasms

SponsorTrials
GlaxoSmithKline9
Tesaro3
USWM CT2
EpicentRx1
OriCell Therapeutics1

Sponsors with the most current trials registered for this condition.

06

Questions about Johnson & Johnson Enterprise Innovation trials

How many clinical trials does Johnson & Johnson Enterprise Innovation sponsor?

Johnson & Johnson Enterprise Innovation is the lead sponsor of 6 current trials on ClinicalTrials.gov in our USA, UK, China and India registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Johnson & Johnson Enterprise Innovation trials recruiting?

Yes. 5 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Johnson & Johnson Enterprise Innovation testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are Cetrelimab (3), JNJ-90301900 (3), Carboplatin (1), Cetuximab (1) and Cisplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.